Divya A Parikh

Oncologist with an interest in Health Services Research and GU Oncology

[Jennifer Caswell-Jin @caswell_jin]

If you have ever been diagnosed with stage 0-3 breast cancer, please consider helping Stanford breast cancer researchers understand your perspectives on a new kind of clinical trial by filling out this short survey: https://t.co/yNmowV9h0s #bcsm (retweets appreciated!)

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

How do we overcome multi-factorial barriers to receipt of high quality cancer treatments? Dr @meera_ragavan at @ASCO #ASCOQLTY22 #PharmacoEquity

[Divya A Parikh @DivyaParikhMD]

Pembrolizumab for non-muscle-invasive bladder cancer – is it worth the cost? @arkhaki @SWilliams_MD

https://t.co/e8T1coedk8

[ASCO @ASCO]

“A seemingly harmless Rx can actually cause great economic burden to pts.” – @guptaarjun90 on new @ASCO_pubs #JCOOP article & #ASCOQLTY21 abstract covering 💲 burden of Rx for cancer-related symptoms https://t.co/5keOdtIV3P #financialtoxicity #ASCODailyNews @OncoAlert @UMNews

[Divya A Parikh @DivyaParikhMD]

Such an honor to present at #ASCO quality alongside my brilliant mentor @manalipatelmd! So grateful for opportunity to present our work and the thoughtful discussion by @MBakitas.

[Journal of the @NCCN @JNCCN]

@sandysrimd of @StanfordCancer discusses advances in the management of metastatic castration-resistant #ProstateCancer at the #NCCN21 Virtual Annual Conference: https://t.co/KLaWM267c1 #CRPC #PCSM

[Divya A Parikh @DivyaParikhMD]

Our study of #financialtoxicity in disparate #cancercare systems was published in @ASCO_pubs #JCOOP! Thanks to the collaborative team @VAPaloAlto @StanfordCancer and SCVMC @meera_ragavan @ritikulocyte @manalipatelmd

https://t.co/fA062lsGY4

[Enrique Soto @EnriqueSoto8]

So tragic that in the wealthiest country in the world the main driving forces behind treatment preferences in #breastcancer are cost and ability to get back to work ASAP #ASCOQLTY20 @asco #healthequity

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

As #ASCO20 wraps, the US remains in turmoil. For those unable to see the inequities at the root of this strife, I will highlight 1 graph from our study. Even as we make progress over time, FAR MORE black patients die from #cancer than white patients.

This is not a just society.

[Divya A Parikh @DivyaParikhMD]

We are conducting a study on the impact of #COVID19 on cancer #providers and their practice. Help us inform ways to improve #cancercare and change policy by taking our provider survey: https://t.co/B1LxzSndvn

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Great guide for #GUcancers in uncharted times. We should consider when discussing our own practices tomorrow @Daniel_J_George @DukeGUCancer

[David Gandara @drgandara]

Congratulations to the authors on publication of this patient-inclusive registry data for ROS1+ cancers. Characteristics of Patients With ROS1+ Cancers: Results From First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository | JCO Oncology Practice https://t.co/eOuN26Rcrc

[Divya A Parikh @DivyaParikhMD]

A Call to Action Toward Patient Centricity: GU Cancers Symposium to Feature More Financial and Quality-of-Life Research https://t.co/Sst0Gnwl68

[Sandy Srinivas @sandysrimd]

Huge cost savings with docetaxel vs abiraterone in HSPC. https://t.co/Jc1lTzNNBV

[Robert S Miller, MD, FACP, FASCO, FAMIA-he/him @rsm2800]

https://t.co/y4XCpyioZw @DrWinkfield #ASCOQLTY19

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

Too often people are #underinsured and financially burdened by the cost of #cancer care. Faced with a choice between their money and their lives, some patients lose both.
Proud of our #graphicmedicine OP-ED in @latimes @NathanAGray #financialtoxicity
https://t.co/9sahQzl0MZ

[Ethan Basch @EthanBasch1]

Patient-reported outcomes are widely collected in routine care through Epic at @UofR, by >240k patients with >98% compliance - but clinicians only use the #PRO data 40% of the time - showing need to engage clinicians @clevinger_kc @FDAOncology @ASCO @pkluetz

[Yousuf Zafar, MD MHS @yzafar]

I'm honored to discuss plenary LBA1, a study on healthcare access, equity, & real-world data--topics of global relevance

A non-traditional @ASCO plenary deserves a non-traditional approach so I'm live tweeting my talk thanks to @DukeGUCancer! #ASCO19 #ASCOhealthequity Pls share!